Lineage Cell Therapeutics Inc (LCTX) Stock Price & News - Google Finance (2024)

Markets

US

Europe

Asia

Currencies

Crypto

Futures

Dow Jones38,701.53+0.34%+130.50Dow Jones38,701.530.34%
Nasdaq16,860.09+0.19%+31.42Nasdaq16,860.090.19%
Russell2,032.85-1.30%-26.83Russell2,032.851.30%
VIX13.31+1.53%+0.20VIX13.311.53%

HomeLCTX • NYSEAMERICAN

Lineage Cell Therapeutics Inc

$0.97

Jun 4, 3:58:32 PM GMT-4 · USD · NYSEAMERICAN · Disclaimer

Key events shows relevant news articles on days with large price movements

Key events shows relevant news articles on days with large price movements

Key events shows relevant news articles on days with large price movements

Geron Corp

$3.99

GERN4.05%

Crispr Therapeutics AG

$58.30

CRSP2.01%

Unity Biotechnology Inc

$1.59

UBX0.00%

Anavex Life Sciences Corp

$4.13

AVXL2.61%

Acumen Pharmaceuticals Inc

$2.75

ABOS0.18%

MyMD Pharmaceuticals Inc

$1.90

MYMD3.06%

Longeveron Inc

$1.03

LGVN0.96%

MeiraGTx Holdings PLC

$4.93

MGTX0.20%

Gevo Inc

$0.65

GEVO0.80%

Verastem Inc

$3.70

VSTM6.09%

Market news

Financials

Income Statement

Revenue

Net income

(USD)Mar 2024info

Fiscal Q1 2024 ended 3/31/24. Reported on 5/9/24.

Y/Y change

Revenue

The total amount of income generated by the sale of goods or services related to the company's primary operations

1.44M-39.48%

Operating expense

Represents the total incurred expenses through normal operations

5.14M4.30%

Net income

Company’s earnings for a period net of operating costs, taxes, and interest

-6.54M-49.63%

Net profit margin

Measures how much net income or profit is generated as a percentage of revenue.

-453.05-147.24%

Earnings per share

Represents the company's profit divided by the outstanding shares of its common stock.

-0.04-54.62%

EBITDA

Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circ*mstances

-6.49M-0.23%

Effective tax rate

The percent of their income that a corporation pays in taxes

Total assets

Total liabilities

(USD)Mar 2024info

Fiscal Q1 2024 ended 3/31/24. Reported on 5/9/24.

Y/Y change

Cash and short-term investments

Investments that are relatively liquid and have maturities between 3 months and one year

43.62M-6.82%

Total assets

The total amount of assets owned by a company

108.48M-4.17%

Total liabilities

Sum of the combined debts a company owes

37.49M-15.16%

Total equity

The value of subtracting the total liabilities from the total assets of a company

70.99M

Shares outstanding

Total number of common shares outstanding as of the latest date disclosed in a financial filing

188.80M

Price to book

A ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock

2.68

Return on assets

A financial ratio that shows a company’s profitability compared to its assets

-15.90%

Return on capital

Company’s return above the average cost it pays for its debt and equity capital

-23.92%

Net change in cash

(USD)Mar 2024info

Fiscal Q1 2024 ended 3/31/24. Reported on 5/9/24.

Y/Y change

Net income

Company’s earnings for a period net of operating costs, taxes, and interest

-6.54M-49.63%

Cash from operations

Net cash used or generated for core business activities

-5.78M48.56%

Cash from investing

Net cash used or generated in investing activities such as purchasing assets

-38.00K-100.25%

Cash from financing

Net cash used or generated in financing activities such as dividend payments and loans

14.02M1,402,000.00%

Net change in cash

The amount by which a company's cash balance increases or decreases in an accounting period

8.13M99.02%

Free cash flow

Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments

-3.30M41.32%

Stock

Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned

US listed security

Listed on NYSEAMERICAN

Previous close

The last closing price

$1.02

Day range

The range between the high and low prices over the past day

$0.97 - $1.06

Year range

The range between the high and low prices over the past 52 weeks

$0.84 - $1.61

Market cap

A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.

183.78M USD

Avg Volume

The average number of shares traded each day over the past 30 days

1.12M

P/E ratio

The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks

-

Dividend yield

The ratio of annual dividend to current share price that estimates the dividend return of a stock

-

About

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia

Founded

1990

Employees

72

Discover more

You may be interested in

info

This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more

IndexTA-35 Index2,008.260.55%
IndexDow Jones Industrial Average38,701.530.34%
IndexNasdaq-10018,658.670.31%
TSLATesla Inc$174.970.75%
IndexTA-125 Index1,994.210.50%
AAPLApple Inc$194.390.18%
IndexVIX13.311.53%
AMZNAmazon.com Inc$179.410.60%
INTCIntel Corp$30.040.84%
IndexNasdaq Composite16,860.090.19%
BABAAlibaba Group Holding Ltd - ADR$78.310.49%
WIXWix.Com Ltd$164.341.38%
BABoeing Co$188.021.58%
METAMeta Platforms Inc$477.140.073%
MSFTMicrosoft Corp$416.140.63%
NFLXNetflix Inc$631.580.35%
NVDANVIDIA Corp$1,164.331.25%

People also search for

GERNGeron Corp$3.994.05%
CRSPCrispr Therapeutics AG$58.302.01%
UBXUnity Biotechnology Inc$1.590.00%
AVXLAnavex Life Sciences Corp$4.132.61%
ABOSAcumen Pharmaceuticals Inc$2.750.18%
MYMDMyMD Pharmaceuticals Inc$1.903.06%
LGVNLongeveron Inc$1.030.96%
MGTXMeiraGTx Holdings PLC$4.930.20%
GEVOGevo Inc$0.650.80%
VSTMVerastem Inc$3.706.09%
QUBTQuantum Computing Inc$0.691.61%
XERSXeris Biopharma Holdings Inc$2.335.10%
RGLSRegulus Therapeutics Inc$2.220.23%
VYGRVoyager Therapeutics Inc$8.501.73%
KTRAKintara Therapeutics Inc$0.2218.11%
NWBONorthwest Biotherapeutics Inc$0.494.04%
BLUEbluebird bio Inc$0.960.062%

Lineage Cell Therapeutics Inc (LCTX) Stock Price & News - Google Finance (7)HelpSend feedbackPrivacyTermsDisclaimer

Lineage Cell Therapeutics Inc (LCTX) Stock Price & News - Google Finance (2024)

References

Top Articles
Latest Posts
Article information

Author: Jonah Leffler

Last Updated:

Views: 6002

Rating: 4.4 / 5 (45 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Jonah Leffler

Birthday: 1997-10-27

Address: 8987 Kieth Ports, Luettgenland, CT 54657-9808

Phone: +2611128251586

Job: Mining Supervisor

Hobby: Worldbuilding, Electronics, Amateur radio, Skiing, Cycling, Jogging, Taxidermy

Introduction: My name is Jonah Leffler, I am a determined, faithful, outstanding, inexpensive, cheerful, determined, smiling person who loves writing and wants to share my knowledge and understanding with you.